The clinical relevance of recognizing mPV was demonstrated in a recent study on 66 JAK2-mutated patients younger than 40 years who revealed a higher risk of thrombosis compared with a control group of 97 cases with overt PV due to the less frequent use of phlebotomies or cytoreductive treatment.61 Altogether based on these clinical findings and the fact that BM morphology is superimposable to that of overt PV,62 according to the original 2008 criteria,3, 4 it makes little sense that the term mPV is maintained, because it may be argued that this entity is in fact fully consistent with PV. Here, JAK2 is linked to acquired polycythemia vera.